M&A Deal Summary |
|
|---|---|
| Date | 2014-08-06 |
| Target | Santaris Pharma A/S |
| Sector | Life Science |
| Buyer(s) | Roche |
| Sellers(s) | Gilde Healthcare |
| Deal Type | Add-on Acquisition |
| Deal Value | 250M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1896 |
| Sector | Life Science |
| Employees | 100,920 |
| Revenue | 60.4B CHF (2023) |
Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 19 of 42 |
| Sector (Life Science) | 12 of 29 |
| Type (Add-on Acquisition) | 17 of 35 |
| Country (Denmark) | 1 of 1 |
| Year (2014) | 2 of 5 |
| Size (of disclosed) | 18 of 29 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-06-02 |
Genia Technologies
Mountain View, California, United States Genia is developing a potentially disruptive next generation sequencing technology with integrated circuits enabling massively parallel, single-molecule DNA sequencing. |
Buy | $125M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-08-24 |
InterMune
Brisbane, California, United States InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. |
Buy | $8.3B |
| Category | Private Equity Firm |
|---|---|
| Founded | 1999 |
| PE ASSETS | 2.6B EUR |
| Size | Large |
| Type | Sector Focused |
Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 30 |
| Sector (Life Science) | 8 of 16 |
| Type (Add-on Acquisition) | 6 of 15 |
| Country (Denmark) | 1 of 3 |
| Year (2014) | 2 of 6 |
| Size (of disclosed) | 1 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-04-07 |
Vapotherm
Exeter, New Hampshire, United States Vapotherm, Inc. is a privately held manufacturer of advanced respiratory care devices based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-08-26 |
Sapiens Steering Brain Stimulation
Munich, Germany Sapiens Steering Brain Stimulation GmbH is developing a Deep Brain Stimulation (DBS) system for patients suffering from brain disorders such as Parkinsons disease. Sapiens innovative solution is an advanced DBS lead with 40 individual stimulation points. |
Sell | $200M |
